Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Survodutide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Boehringer, Zealand's Obesity Drug Resembles Novo's Wegovy
    Boehringer, Zealand's Obesity Drug Resembles Novo's Wegovy

    29 Apr 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/boehringer-zealands-obesity-drug-more-akin-to-novos-wegovy-in-phase-3

    BIOSPACE
    29 Apr 2026
    Share Share
    Zealand Pharma Reveals Boehringer's Dual Agonist Survodutide
    Zealand Pharma Reveals Boehringer's Dual Agonist Survodutide

    28 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/28/3282220/0/en/zealand-pharma-announces-boehringer-ingelheim-s-novel-glucagon-glp-1-dual-agonist-survodutide-achieved-significant-weight-loss-of-16-6-delivering-meaningful-metabolic-improvement-i.html

    GLOBENEWSWIRE
    28 Apr 2026
    Share Share
    Zealand Pharma Unveils Metabolic Frontier 2030 Strategy
    Zealand Pharma Unveils Metabolic Frontier 2030 Strategy

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3203618/0/en/Zealand-Pharma-outlines-Metabolic-Frontier-2030-strategy-to-become-a-generational-biotech-leader-in-obesity-and-metabolic-health.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Zealand: Boehringer's Survodutide Cut Fibrosis, No MASH Worsening
    Zealand: Boehringer's Survodutide Cut Fibrosis, No MASH Worsening

    07 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/07/2895248/0/en/Zealand-Pharma-announces-that-Boehringer-Ingelheim-s-survodutide-demonstrates-breakthrough-improvement-in-liver-fibrosis-with-no-worsening-of-MASH-in-64-5-of-patients-with-F2-and-F.html

    GLOBENEWSWIRE
    07 Jun 2024
    Share Share
    Boehringer's Survodutide Cut Fibrosis, No MASH Worsening In 64.5%
    Boehringer's Survodutide Cut Fibrosis, No MASH Worsening In 64.5%

    07 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/07/2895231/0/en/Boehringer-Ingelheim-s-survodutide-shows-breakthrough-improvement-in-liver-fibrosis-with-no-worsening-of-MASH-in-64-5-of-patients-with-F2-and-F3-fibrosis.html

    GLOBENEWSWIRE
    07 Jun 2024
    Share Share
    Zealand: Boehringer To Present Positive Survodutide MASH Trial At EASL
    Zealand: Boehringer To Present Positive Survodutide MASH Trial At EASL

    06 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/06/2894525/0/en/Zealand-Pharma-announces-that-Boehringer-Ingelheim-will-present-positive-results-from-Phase-2-trial-with-survodutide-in-MASH-at-EASL.html

    GLOBENEWSWIRE
    06 Jun 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.